New chemical technology leads to better targeted therapeutics against high-risk leukemia in the lab

Scientists from St. Jude Children’s Research Hospital have created an LCK targeted PROTAC, demonstrating its enhanced ability to kill T-cell acute lymphoblastic leukemia cells.

Read more: https://www.stjude.org/media-resources/news-releases/2022-medicine-science-news/new-technology-leads-to-better-therapeutics-against-high-risk-leukemia.html